A systematic review of decrementally cost-effective health technologies and case studies

Autor: Scarica, R., Chavez Pacheco, X., K. Dupont, JC, Rochaix, L., Durand Zaleski, I, Darlington, M.
Rok vydání: 2021
Předmět:
DOI: 10.5281/zenodo.5032372
Popis: Background: HTA guidance has been mostly driven by situations where innovative and usually more expensive technologies are compared to the prevailing standards of care. Cheaper and less effective interventions have usually received scarce attention, although for several reasons strategies with minimal individual benefit losses might produce collective health gains. Objectives and methods: This systematic review of health economic evaluations aims to identify interventions in the south-west quadrant of the cost-effectiveness plane to procure a list of candidate decrementally cost-effective (d-CE) technologies. It provides the primary evidence necessary to support the development of a toolbox for local HTA projects for implementation of d-CE strategies. European Health Authorities’ decisions for a subset of these candidate technologies were reviewed. The obstacles and the potential drivers of implementation from the different stakeholders’ perspectives were documented. Findings: After filtering 3,689 studies found through a systematic review, 94 d-CE health technologies (HT) were identified. Nearly a third were services (n=29) and nearly a third were drugs (n=27). Only one non-pharmaceutical intervention (NPI) was identified and it seems that economic data for NPIs is rare. Seven HTs were selected from the list of d-CE technologies in order to focus on the decisions made by HTA agencies and medical associations. Among these, two were selected in order to perform budget impact analyses that explore the potential opportunity cost that could be generated by implementation of d-CE interventions. For example, the budget savings over a three-year period following an increase in prescription of conventional DMARDs for Rheumatoid Arthritis would be €51 million from the perspective of the French Social Health Insurance for an average loss of 0.017 QALYs.
Databáze: OpenAIRE